Nathanya Baez Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nathanya Baez Hernandez has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Maria Bano
Department of Pediatrics Children's Medical Center of Dallas/University of Texas Southwestern Dallas Texas USA
3 shared publications - Ryan Butts
Department of Pediatrics Children's Medical Center of Dallas/University of Texas Southwestern Dallas Texas USA
3 shared publications - Alyssa Power
Department of Pediatrics UT Southwestern Medical Center and Children’s Medical Center Dallas Texas USA
2 shared publications - David L. Sutcliffe
Division of Pediatric Cardiology, Children's Mercy Hospital, Kansas City, Missouri, USA
2 shared publications - Richard Kirk
Division of Pediatric Cardiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Ryan Robert Davies
UT Southwestern Med Ctr, Dept Cardiovasc & Thorac Surg, 1935 Med Dist Dr,MC B3-410, Dallas, TX 75235 USA
2 shared publications
Latest Publications
- 8 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70482
Donor‐Derived Cell‐Free DNA –Guided Rejection Surveillance in Medium‐ and High‐Risk Pediatric Heart Transplant Recipients: A Single‐Center Experience
Background: Allograft rejection remains a leading cause of morbidity in pediatric heart transplant (HT) recipients. Endomyocardial biopsy (EMB), the standard for surveillance, is invasive and resource‐intensive. Donor‐derived cell‐free DNA (dd‐cfDNA) is a promising noninvasive biomarker, though pediatric data remain limited. Methods: We performed a retrospective cohort study of 50 pediatric HT recipients (< 18 years) at a single quaternary center. Medium‐ and high‐risk patients managed with a dd‐cfDNA–guided protocol ( n = 25) were compared with a historical biopsy‐based cohort ( n = 25). Primary outcomes included biopsy frequency and incidence of clinically significant rejection (ACR ≥ 2R, pAMR ≥ 2, or treated rejection) over the first year post‐HT. Results: The dd‐cfDNA group underwent fewer biopsies ( p = 0.005), with only 4% requiring ≥ 5 biopsies versus 16% in controls. There was no difference in 12‐month rejection incidence (39% vs. 25%, p = 0.99). Biopsy yield was higher in the dd‐cfDNA group ( p = 0.053). Among rejection episodes, 88% were preceded by increased dd‐cfDNA, with a significant relative rise within 30 days (104%, p = 0.021). Conclusion: In medium‐ and high‐risk pediatric HT recipients, dd‐cfDNA–guided surveillance reduced biopsy utilization without increasing rejection. These findings support dd‐cfDNA as a clinically useful adjunct to optimize surveillance strategies in pediatric transplantation.
- 8 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70482
Donor‐Derived Cell‐Free DNA –Guided Rejection Surveillance in Medium‐ and High‐Risk Pediatric Heart Transplant Recipients: A Single‐Center Experience
Background: Allograft rejection remains a leading cause of morbidity in pediatric heart transplant (HT) recipients. Endomyocardial biopsy (EMB), the standard for surveillance, is invasive and resource‐intensive. Donor‐derived cell‐free DNA (dd‐cfDNA) is a promising noninvasive biomarker, though pediatric data remain limited. Methods: We performed a retrospective cohort study of 50 pediatric HT recipients (< 18 years) at a single quaternary center. Medium‐ and high‐risk patients managed with a dd‐cfDNA–guided protocol ( n = 25) were compared with a historical biopsy‐based cohort ( n = 25). Primary outcomes included biopsy frequency and incidence of clinically significant rejection (ACR ≥ 2R, pAMR ≥ 2, or treated rejection) over the first year post‐HT. Results: The dd‐cfDNA group underwent fewer biopsies ( p = 0.005), with only 4% requiring ≥ 5 biopsies versus 16% in controls. There was no difference in 12‐month rejection incidence (39% vs. 25%, p = 0.99). Biopsy yield was higher in the dd‐cfDNA group ( p = 0.053). Among rejection episodes, 88% were preceded by increased dd‐cfDNA, with a significant relative rise within 30 days (104%, p = 0.021). Conclusion: In medium‐ and high‐risk pediatric HT recipients, dd‐cfDNA–guided surveillance reduced biopsy utilization without increasing rejection. These findings support dd‐cfDNA as a clinically useful adjunct to optimize surveillance strategies in pediatric transplantation.
- Open Access
- 28 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (9) , 718-727
The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, abnormal results on exercise stress testing are predictive of heart failure outcomes. Our goal was to determine whether an abnormal exercise response is associated with adverse outcomes in pediatric patients with HCM. Methods: In an international cohort study including 20 centers, phenotype-positive patients with primary HCM who were z scores, higher resting left ventricular outflow tract gradient, and higher frequency of myectomy compared with participants with normal test results ( P P =0.005). Patients with exercise-induced ischemia were most likely to experience all-cause death or transplant (hazard ratio, 4.86 [95% CI, 1.69–13.99]), followed by those with an abnormal blood pressure response (hazard ratio, 3.19 [95% CI, 1.32–7.71]). Exercise-induced ischemia was also independently associated with lower SCD event-free survival (hazard ratio, 3.32 [95% CI, 1.27–8.70]). Exercise-induced ectopy was not associated with survival. Conclusions: Exercise abnormalities are common in childhood HCM. An abnormal exercise test result was independently associated with lower transplant-free survival, especially in those with an ischemic or abnormal blood pressure response with exercise. Exercise-induced ischemia was also independently associated with SCD events. These findings argue for routine exercise testing in childhood HCM as part of ongoing risk assessment.
- 28 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (9) , 718-727
Open AccessThe Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, abnormal results on exercise stress testing are predictive of heart failure outcomes. Our goal was to determine whether an abnormal exercise response is associated with adverse outcomes in pediatric patients with HCM. Methods: In an international cohort study including 20 centers, phenotype-positive patients with primary HCM who were z scores, higher resting left ventricular outflow tract gradient, and higher frequency of myectomy compared with participants with normal test results ( P P =0.005). Patients with exercise-induced ischemia were most likely to experience all-cause death or transplant (hazard ratio, 4.86 [95% CI, 1.69–13.99]), followed by those with an abnormal blood pressure response (hazard ratio, 3.19 [95% CI, 1.32–7.71]). Exercise-induced ischemia was also independently associated with lower SCD event-free survival (hazard ratio, 3.32 [95% CI, 1.27–8.70]). Exercise-induced ectopy was not associated with survival. Conclusions: Exercise abnormalities are common in childhood HCM. An abnormal exercise test result was independently associated with lower transplant-free survival, especially in those with an ischemic or abnormal blood pressure response with exercise. Exercise-induced ischemia was also independently associated with SCD events. These findings argue for routine exercise testing in childhood HCM as part of ongoing risk assessment.
- 17 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (3) , e14214
Rejection surveillance in pediatric heart transplant recipients: Critical reflection on the role of frequent and long‐term routine surveillance endomyocardial biopsies and comprehensive review of non‐invasive rejection screening tools
Background: Despite significant medical advances in the field of pediatric heart transplantation (HT), acute rejection remains an important cause of morbidity and mortality. Endomyocardial biopsy (EMB) remains the gold‐standard method for diagnosing rejection but is an invasive, expensive, and stressful process. Given the potential adverse consequences of rejection, routine post‐transplant rejection surveillance protocols incorporating EMB are widely employed to detect asymptomatic rejection. Each center employs their own specific routine rejection surveillance protocol, with no consensus on the optimal approach and with high inter‐center variability. The utility of high‐frequency and long‐term routine surveillance biopsies (RSB) in pediatric HT has been called into question.Methods: Sources for this comprehensive review were primarily identified through searches in biomedical databases including MEDLINE and Embase.Results: The available literature suggests that the diagnostic yield of RSB is low beyond the first year post‐HT and that a reduction in RSB intensity from high‐frequency to low‐frequency can be done safely with no impact on early and mid‐term survival. Though there are emerging non‐invasive methods of detecting asymptomatic rejection, the evidence is not yet strong enough for any test to replace EMB.Conclusion: Overall, pediatric HT centers in North America should likely be doing fewer RSB than are currently performed. Risk factors for rejection should be considered when designing the optimal rejection surveillance strategy. Noninvasive testing including emerging biomarkers may have a complementary role to aid in safely reducing the need for RSB.
- 17 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (3) , e14214
Rejection surveillance in pediatric heart transplant recipients: Critical reflection on the role of frequent and long‐term routine surveillance endomyocardial biopsies and comprehensive review of non‐invasive rejection screening tools
Background: Despite significant medical advances in the field of pediatric heart transplantation (HT), acute rejection remains an important cause of morbidity and mortality. Endomyocardial biopsy (EMB) remains the gold‐standard method for diagnosing rejection but is an invasive, expensive, and stressful process. Given the potential adverse consequences of rejection, routine post‐transplant rejection surveillance protocols incorporating EMB are widely employed to detect asymptomatic rejection. Each center employs their own specific routine rejection surveillance protocol, with no consensus on the optimal approach and with high inter‐center variability. The utility of high‐frequency and long‐term routine surveillance biopsies (RSB) in pediatric HT has been called into question.Methods: Sources for this comprehensive review were primarily identified through searches in biomedical databases including MEDLINE and Embase.Results: The available literature suggests that the diagnostic yield of RSB is low beyond the first year post‐HT and that a reduction in RSB intensity from high‐frequency to low‐frequency can be done safely with no impact on early and mid‐term survival. Though there are emerging non‐invasive methods of detecting asymptomatic rejection, the evidence is not yet strong enough for any test to replace EMB.Conclusion: Overall, pediatric HT centers in North America should likely be doing fewer RSB than are currently performed. Risk factors for rejection should be considered when designing the optimal rejection surveillance strategy. Noninvasive testing including emerging biomarkers may have a complementary role to aid in safely reducing the need for RSB.
- 14 June 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (6) , e13764
A comprehensive strategy in donor acceptance: Impact on pediatric waitlist and heart transplant outcomes
Significant inter‐ and intra‐center practice variability is present in pediatric donor heart acceptability. This may contribute to variation in the donor refusal rate and may impact waitlist time, morbidity, mortality, and transplant rates. In order to reduce practice variability, our center developed and implemented a comprehensive strategy regarding donor acceptance in September 2017. The aim of this study was to assess the impact of this strategy on waitlist time and outcomes as well as early post‐transplant outcomes. We performed a single‐center, retrospective analysis of all pediatric (P = .006. The number of donor refusals was lower in Group 2 (1, IQR 0‐2.2) vs Group 1 (4, IQR 2‐19); P < .001. The percentage of refused donors with normal function (Left ventricular ejection fraction > 50%) was lower in Group 2 vs Group 1 (53% vs 84%; P < .001). Difference in removal from the waitlist for death or deterioration in Group 2 vs Group 1 (n = 2, 7% vs n = 7, 20%, P = .18) did not reach statistical significance. There was no difference in post‐transplant outcomes between groups. The waitlist time and donor refusals significantly decreased after implementation of a comprehensive donor acceptance strategy without impacting transplant outcomes. This analysis supports the need for a comprehensive approach to donor organ acceptance within a pediatric transplant center.
- 14 June 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (6) , e13764
A comprehensive strategy in donor acceptance: Impact on pediatric waitlist and heart transplant outcomes
Significant inter‐ and intra‐center practice variability is present in pediatric donor heart acceptability. This may contribute to variation in the donor refusal rate and may impact waitlist time, morbidity, mortality, and transplant rates. In order to reduce practice variability, our center developed and implemented a comprehensive strategy regarding donor acceptance in September 2017. The aim of this study was to assess the impact of this strategy on waitlist time and outcomes as well as early post‐transplant outcomes. We performed a single‐center, retrospective analysis of all pediatric (P = .006. The number of donor refusals was lower in Group 2 (1, IQR 0‐2.2) vs Group 1 (4, IQR 2‐19); P < .001. The percentage of refused donors with normal function (Left ventricular ejection fraction > 50%) was lower in Group 2 vs Group 1 (53% vs 84%; P < .001). Difference in removal from the waitlist for death or deterioration in Group 2 vs Group 1 (n = 2, 7% vs n = 7, 20%, P = .18) did not reach statistical significance. There was no difference in post‐transplant outcomes between groups. The waitlist time and donor refusals significantly decreased after implementation of a comprehensive donor acceptance strategy without impacting transplant outcomes. This analysis supports the need for a comprehensive approach to donor organ acceptance within a pediatric transplant center.
- 29 February 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (4) , e13688
Heart transplantation in an infant with Williams‐Beuren syndrome and rapidly progressive ischemic cardiomyopathy
Ischemic cardiomyopathy with resultant refractory HF may occur in patients with WBS, often as the result of coronary involvement with SVAS. The rapid development of arteriopathy at a young age raises concerns regarding transplant candidacy due to progressive stenoses at other arterial sites with potential detrimental impact on long‐term heart graft function. We report a 2‐month‐old male infant diagnosed with mild aortic stenosis during the neonatal period, but subsequently developed rapidly progressive supravalvar and coronary artery stenoses leading to cardiogenic shock due to myocardial ischemia. The presentation led to the diagnosis of WBS. He required prolonged CPR including ECMO therapy. He subsequently underwent LVAD implantation as bridge to transplant and 4 days later heart transplantation. His post‐operative course was complicated by prolonged mechanical ventilation and extended intensive care unit and hospital stays. However, at follow‐up 18 months post‐transplant he continues to have normal graft function with mild, non‐progressive residual coarctation of aorta and non‐progressive moderately hypoplastic pulmonary arteries.
- 29 February 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (4) , e13688
Heart transplantation in an infant with Williams‐Beuren syndrome and rapidly progressive ischemic cardiomyopathy
Ischemic cardiomyopathy with resultant refractory HF may occur in patients with WBS, often as the result of coronary involvement with SVAS. The rapid development of arteriopathy at a young age raises concerns regarding transplant candidacy due to progressive stenoses at other arterial sites with potential detrimental impact on long‐term heart graft function. We report a 2‐month‐old male infant diagnosed with mild aortic stenosis during the neonatal period, but subsequently developed rapidly progressive supravalvar and coronary artery stenoses leading to cardiogenic shock due to myocardial ischemia. The presentation led to the diagnosis of WBS. He required prolonged CPR including ECMO therapy. He subsequently underwent LVAD implantation as bridge to transplant and 4 days later heart transplantation. His post‐operative course was complicated by prolonged mechanical ventilation and extended intensive care unit and hospital stays. However, at follow‐up 18 months post‐transplant he continues to have normal graft function with mild, non‐progressive residual coarctation of aorta and non‐progressive moderately hypoplastic pulmonary arteries.
- 9 December 2019
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (5) , 1301-1308.e2
Utilization and outcomes in biventricular assist device support in pediatrics
- 9 December 2019
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (5) , 1301-1308.e2
Utilization and outcomes in biventricular assist device support in pediatrics